Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company, announced it will release its second quarter financial results for fiscal year 2025 on November 14, 2024. A live conference call to discuss these results and provide a business update is scheduled for November 15, 2024, at 11:30 AM EST. Stockholders can submit questions to be addressed during the call, with general queries due by November 13 and financial questions by November 14. The call will be accessible via dial-in numbers and an audio replay will be available on the company's website.
Elite Pharmaceuticals (OTCQB: ELTP), un'azienda farmaceutica specializzata, ha annunciato che pubblicherà i risultati finanziari del secondo trimestre per l'anno fiscale 2025 il 14 novembre 2024. Una conferenza telefonica in diretta per discutere di questi risultati e fornire un aggiornamento aziendale è programmata per il 15 novembre 2024, alle 11:30 AM EST. Gli azionisti possono inviare domande da trattare durante la chiamata, con le domande generali da presentare entro il 13 novembre e le domande finanziarie entro il 14 novembre. La chiamata sarà accessibile tramite numeri di telefonia e ci sarà una registrazione audio disponibile sul sito web dell'azienda.
Elite Pharmaceuticals (OTCQB: ELTP), una empresa farmacéutica especializada, anunció que publicará sus resultados financieros del segundo trimestre del año fiscal 2025 el 14 de noviembre de 2024. Una llamada de conferencia en vivo para discutir estos resultados y proporcionar una actualización empresarial está programada para el 15 de noviembre de 2024, a las 11:30 AM EST. Los accionistas pueden enviar preguntas para abordar durante la llamada, con preguntas generales debiendo ser enviadas antes del 13 de noviembre y preguntas financieras antes del 14 de noviembre. La llamada será accesible a través de números de marcado y habrá una reproducción de audio disponible en el sitio web de la empresa.
엘리트 제약(OTCQB: ELTP)은 특수 제약 회사로, 2024년 11월 14일에 2025 회계연도 2분기 재무 결과를 발표할 예정이라고 발표했습니다. 이 결과를 논의하고 사업 업데이트를 제공하기 위한 실시간 컨퍼런스 콜은 2024년 11월 15일 오전 11시 30분(EST)에 예정되어 있습니다. 주주들은 통화 중에 다룰 질문을 제출할 수 있으며, 일반적인 질문은 11월 13일까지, 재무 질문은 11월 14일까지 제출해야 합니다. 이 콜은 다이얼 인 번호를 통해 접근 가능하며, 회사 웹사이트에서 오디오 재생이 제공될 것입니다.
Elite Pharmaceuticals (OTCQB: ELTP), une entreprise pharmaceutique spécialisée, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre pour l'exercice 2025 le 14 novembre 2024. Une conférence téléphonique en direct pour discuter de ces résultats et fournir une mise à jour sur l'entreprise est prévue pour le 15 novembre 2024 à 11h30 EST. Les actionnaires peuvent soumettre des questions à aborder lors de l'appel, les questions générales devant être soumises avant le 13 novembre et les questions financières avant le 14 novembre. L'appel sera accessible par des numéros de composition et une rediffusion audio sera disponible sur le site web de l'entreprise.
Elite Pharmaceuticals (OTCQB: ELTP), ein spezialisiertes Pharmaunternehmen, gab bekannt, dass es am 14. November 2024 die finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 veröffentlichen wird. Eine Live-Konferenzschaltung zur Diskussion dieser Ergebnisse und zur Bereitstellung eines Business-Updates ist für den 15. November 2024 um 11:30 Uhr EST geplant. Aktionäre können Fragen einreichen, die während des Anrufs behandelt werden, wobei allgemeine Anfragen bis zum 13. November und finanzielle Fragen bis zum 14. November fällig sind. Der Anruf ist über Einwahlnummern zugänglich, und eine Audio-Wiederholung wird auf der Unternehmenswebsite verfügbar sein.
- Elite Pharmaceuticals will release its second quarter financial results for fiscal year 2025 on November 14, 2024.
- A live conference call to discuss financial results and provide updates is scheduled for November 15, 2024, at 11:30 AM EST.
- None.
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024
Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
| Date: | November 15, 2024 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EST on Wednesday, November 13, 2024 Financial questions by 7:00 PM EST on Thursday, November 14, 2024 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229053
FAQ
When will Elite Pharmaceuticals release its second quarter financial results for fiscal year 2025?
When is the Elite Pharmaceuticals conference call to discuss the second quarter financial results?
What is the dial-in number for the Elite Pharmaceuticals conference call?
Where can I submit questions for the Elite Pharmaceuticals conference call?
Where can I find the audio replay of the Elite Pharmaceuticals conference call?
